Skip to main content
SpringerLink
Log in

Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Atrial fibrillation is a commonly encountered arrhythmia associated with increased risk for thromboembolic events. Anticoagulation is necessary to decrease the risk of ischemic stroke. Traditionally, warfarin has been the only oral pharmacotherapeutic option for long-term anticoagulation in patients with nonvalvular atrial fibrillation (NVAF). Recently, non-vitamin K antagonist oral anticoagulants (NOAC), including dabigatran, rivaroxaban, apixaban, and edoxaban, have become available as alternatives for warfarin in the prevention of stroke in patients with NVAF. Recently published atrial fibrillation guidelines contain new recommendations for risk stratification tools in determining the need for anticoagulant therapy and incorporate NOAC pharmacotherapy options for stroke prevention in patients with NVAF. NOACs offer several advantages over warfarin, including the elimination of routine laboratory monitoring, fewer drug and food interactions, and rapid therapeutic onset and offset. However, the lack of antidote in the case of serious bleeding and lack of data for long-term use in patient populations at risk for bleeding is problematic. Older adults are at high risk for thromboembolic and bleeding events as a result of anticoagulation and require special consideration when selecting anticoagulant therapy. The risk of drug accumulation and bleeding is concerning in the presence of renal impairment. The objective of this review is to provide the clinician with an update on the use of NOACs for NVAF, focusing on older adults and patients with renal impairment in light of recently published atrial fibrillation guidelines. Available data on using NOACs in coronary artery stenting, cardioversion, and ablation are also reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Jr., Cigarroa JE, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 (Epub 2014/04/02. Eng).

  2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25.

    PubMed  Google Scholar 

  3. Reinecke H, Brand E, Mesters R, Schabitz WR, Fisher M, Pavenstadt H, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol JASN. 2009;20(4):705–11 (Epub 2008/12/19. eng).

    CAS  Google Scholar 

  4. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(8A):2N–9N (Epub 1998/11/11. eng).

    CAS  PubMed  Google Scholar 

  5. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5.

    CAS  PubMed  Google Scholar 

  6. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005;127(6):2049–56.

    CAS  PubMed  Google Scholar 

  7. Perez-Gomez F, Iriarte JA, Zumalde J, Berjon J, Salvador A, Alegria E, et al. Antithrombotic therapy in elderly patients with atrial fibrillation: effects and bleeding complications: a stratified analysis of the NASPEAF randomized trial. Eur Heart J. 2007;28(8):996–1003.

    CAS  PubMed  Google Scholar 

  8. Quinn GR, Fang MC. Atrial fibrillation: stroke prevention in older adults. Clin Geriatr Med. 2012;28(4):617–34.

    PubMed  Google Scholar 

  9. Deedwania PC. New oral anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2013;126(4):289–96.

    CAS  PubMed  Google Scholar 

  10. Ogbonna KC, Jeffery SM. Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly. Drugs Aging. 2013;30(7):513–25.

    CAS  PubMed  Google Scholar 

  11. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70.

    CAS  PubMed  Google Scholar 

  12. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.

    PubMed  Google Scholar 

  13. Lip GY. Can we predict stroke in atrial fibrillation? Clin Cardiol. 2012;35(S1):21–7.

    PubMed  Google Scholar 

  14. Lane DA, Lip GY. Use of the CHA2DS2-VASc and HAS-BLED scores to aim decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126(7):860–5.

    PubMed  Google Scholar 

  15. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e531S–75S.

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Albert NM. Use of novel anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. Heart Lung. 2014;43(1):48–59.

    PubMed  Google Scholar 

  17. Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013;2(6):e000535.

    PubMed Central  PubMed  Google Scholar 

  18. Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol. 2006;62(5):509–11.

    PubMed Central  PubMed  Google Scholar 

  19. Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 1999;59(3):635–46.

    CAS  PubMed  Google Scholar 

  20. Connolly JP, Eikelboom J, Flaker G, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029–37.

    CAS  PubMed  Google Scholar 

  21. Albert NM. Use of novel anticoagulants for patients with atrial fibrillation: systematic review and clinical implications. Heart Lung. 2014;43:48–59.

    PubMed  Google Scholar 

  22. Cavallari LH, Shin J, Perera MA. Role of pharmacogenomics in the management of traditional and novel anticoagulants. Pharmacotherapy. 2011;31(12):1192–207.

    CAS  PubMed  Google Scholar 

  23. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111(8):4106–12.

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. J Thromb Haemost. 2006;95(5):782–7.

    CAS  Google Scholar 

  25. King CR, Deych E, Milligan P, Eby C, Lenzini P, Grice G, et al. Gamma-glutamyl carboxylase and its influence on warfarin dose. J Thromb Haemost. 2010;104(4):750–4.

    CAS  Google Scholar 

  26. Voora D, Koboldt DC, King CR, Lenzini PA, Eby CS, Porche-Sorbet R, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010;87(4):445–51.

    CAS  PubMed Central  PubMed  Google Scholar 

  27. Holbrook AMPJ, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–106.

    CAS  PubMed  Google Scholar 

  28. Coumadin (package insert). Princeton (NJ): Bristol-Myers Squibb; 2011. Available at: http://packageinserts.bms.com/pi/pi_coumadin.pdf.

  29. Chang CH, Wang YW, Yeh Liu PY, Kao Yang YH. A practical approach to minimize the interaction of dietary vitamin K with warfarin. J Clin Pharm Ther. 2014;39(1):56–60.

    CAS  PubMed  Google Scholar 

  30. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2014. Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.

  31. Eikelboom J. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–14.

    CAS  PubMed  Google Scholar 

  32. Beasley BN, Unger EF, Temple R. Anticoagulant options: why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364(19):1788–90 (Epub 2011/04/15. eng).

    CAS  PubMed  Google Scholar 

  33. Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, et al. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013;62(10):900–8.

    CAS  PubMed  Google Scholar 

  34. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321–8.

    CAS  PubMed  Google Scholar 

  35. Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ. 2014;23(349):g4517.

    Google Scholar 

  36. FDA. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin 2014 [updated July 8, 2014; cited 2014 July 22, 2014]. Available from: http://www.fda.gov/drugs/drugsafety/ucm396470.htm.

  37. Douxfils J. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;6(3):1–12.

    Google Scholar 

  38. Xarelto [package insert]. Titusville, NJ: Jannsen Pharmaceuticals, Inc.; 2014. Available at: http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100.

  39. Patel M. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.

    CAS  PubMed  Google Scholar 

  40. Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2014;3(2):e000521.

    PubMed Central  PubMed  Google Scholar 

  41. Eliquis [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2014. Available at: http://packageinserts.bms.com/pi/pi_eliquis.pdf.

  42. Granger C. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

    CAS  PubMed  Google Scholar 

  43. Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial. Lancet. 2012;17(380):1749–58.

    Google Scholar 

  44. US FDA. FDA approves anti-clotting drug Savaysa 2015 [cited 2015 March 5]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm429523.htm.

  45. Savaysa [package insert]. Parsippany, NJ. Daiichi Sankyo, Inc.; 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf.

  46. Giugliano R. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.

    CAS  PubMed  Google Scholar 

  47. Guyatt G. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2_suppl):7S–47S.

    CAS  PubMed Central  PubMed  Google Scholar 

  48. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.

    PubMed  Google Scholar 

  49. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719–47.

    PubMed  Google Scholar 

  50. Harrington AR, Armstrong EP, Nolan PE Jr, et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676–81.

    PubMed  Google Scholar 

  51. Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498–506.

    PubMed  Google Scholar 

  52. Lip GY, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014;36(2):192–210.

    PubMed  Google Scholar 

  53. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of novel oral anticoagulants in atrial fibrillation; a systematic review and meta-analysis of the literature. Circulation. 2012;13(126):2381–91.

    Google Scholar 

  54. Lip G, Skjoth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60(8):738–46.

    CAS  PubMed  Google Scholar 

  55. Schneeweiss S, Gagne JJ, Patrick AR, Choudry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5(4):480–6.

    PubMed Central  PubMed  Google Scholar 

  56. Ruff RG, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of ransomised trials. Lancet. 2014;15(383):955–62.

    Google Scholar 

  57. Sardar P, Chatterjee S, Herzog E, Nairooz R, Mukherjee D, Halperin JL. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol. 2014;30(8):888–97.

    PubMed  Google Scholar 

  58. Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014;62(5):857–64.

    PubMed  Google Scholar 

  59. Caldeira D, Barra M, Pinto FJ, Ferreira JJ, Costa J. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol. 2014;262(3):516–22.

  60. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013;145(1):105–12 e15.

  61. Sardar P, Chatterjee S, Herzog E, Pekler G, Mushiyev S, Pastori LJ, et al. New oral anticoagulants in patients with cancer: current state of evidence. Am J Ther. 2014.

  62. Shafeeq TT. New oral anticoagulants for atrial fibrillation, are they worth the risk? P T. 2014;39(1):54–64.

    PubMed Central  PubMed  Google Scholar 

  63. Udell J. Hot topics: meta-analysis: how NOACs compared to warfarin in AFib: cardiosource.org; 2014 [cited 2014]. Available from: http://www.acc.org/latest-in-cardiology/articles/2014/07/18/15/33/meta-analysis-how-noacs-compared-to-warfarin-in-afib.

  64. Bauer KA. Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Program. 2013;2013:464–70.

    Google Scholar 

  65. Nutescu WD, Kalus JS, Lewin JJ III, Cipolle MD. Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations. Am J Health Syst Pharm. 2013;1(70):1914–29.

    Google Scholar 

  66. Douxfils J, Mani H, Minet,V et al. Non-VKA oral anticoagulants: accurate measurement of plasma drug concentrations. BioMed Res Int. 2014. Article ID 345138.

  67. Majeed A. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol. 2013;26:191–202.

    CAS  PubMed  Google Scholar 

  68. Siegal DM. Reversal of novel oral anticoagulants in patients woth major bleeding. J Thromb Thrombolysis. 2013;35(3):391–8.

    CAS  PubMed  Google Scholar 

  69. Kaatz S, Crowther M. Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis. 2013;36:195–202.

    CAS  PubMed  Google Scholar 

  70. Eerenberg ES, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. Circulation. 2011;124(14):1573–9.

    CAS  PubMed  Google Scholar 

  71. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34(27):2094–106.

    CAS  PubMed  Google Scholar 

  72. Dugi K. US FDA Grants Breakthrough Therapy Designation to Pradaxa (dabigatran etexilate) specific Investigational Antidote [Boehringer-Ingelheim press release]. Ingelheim, Germany2014 [cited 2014 July 23]. Available from: http://www.boehringer-ingelheim.com/news/news_releases/2014/30_june_2014_dabigatranetexilate.html.

  73. Portola-Pharmaceuticals. Andexanet alpha: FXa inhibitor antidote: Portola Pharmaceuticals; 2014 [cited 2014 July 22]. Available from: http://www.portola.com/clinical-development/andexanet-alfa-prt4445-fxa-inhibitor-antidote.

  74. Peroshpere-Inc. Antidote for New Oral Anticoagulants - PER977: Peroshpere; 2014 [cited 2014 July 22 ]. Available from: http://www.perosphere.com/content/drug/drugcandidates.htm.

  75. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51 (Epub 2009/09/01. eng).

    CAS  PubMed  Google Scholar 

  76. Coppens M, Eikelboom J, Ezekowitz M, et al. Dabigatran versus warfarin in very elderly patients with atrial fibrillation: results from the RE-LY trial [abstract]. Circulation. 2012;126:A15537.

    Google Scholar 

  77. Barton CA, McMillian WD, Raza SS, Keller RE. Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy. 2012;32(5):e103–7.

    PubMed  Google Scholar 

  78. Bene J, Said W, Rannou M, Deheul S, Coupe P, Gautier S. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother. 2012;46(6):e14.

    PubMed  Google Scholar 

  79. Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother. 2012;10(2):160–3 (Epub 2012/03/06. Eng).

    PubMed  Google Scholar 

  80. Chen BC, Sheth NR, Dadzie KA, Smith SW, Nelson LS, Hoffman RS, et al. Hemodialysis for the treatment of pulmonary hemorrhage from dabigatran overdose. Am J Kidney Dis. 2013;62(3):591–4 (Epub 2013/04/20. eng).

    PubMed  Google Scholar 

  81. Chen BC, Viny AD, Garlich FM, Basciano P, Howland MA, Smith SW, et al. Hemorrhagic complications associated with dabigatran use. Clin Toxicol. 2012;50(9):854–7 (Epub 2012/09/14. eng).

    CAS  Google Scholar 

  82. Dumkow LE, Voss JR, Peters M, Jennings DL. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm. 2012;69(19):1646–50 (Epub 2012/09/22. eng).

    CAS  PubMed  Google Scholar 

  83. Dy EA, Shiltz DL. Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother. 2012;46(7–8):e18 (Epub 2012/07/13. eng).

    PubMed  Google Scholar 

  84. Fellows SE, Rosini JM, Curtis JA, Volz EG. Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency. J Emerg Med. 2013;44(2):e221–5.

    PubMed  Google Scholar 

  85. Fountzilas C, George J, Levine R. Dabigatran overdose secondary to acute kidney injury and amiodarone use. N Z Med J. 2013;126(1370):110–2.

    PubMed  Google Scholar 

  86. Freshour JE, Hudson JQ, Stevens AB, Franks AS. Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance. Am J Health Syst Pharm. 2012;69(14):1184–6.

    CAS  PubMed  Google Scholar 

  87. Garber ST, Sivakumar W, Schmidt RH. Neurosurgical complications of direct thrombin inhibitors–catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg. 2012;116(5):1093–6 (Epub 2012/03/08. eng).

    PubMed  Google Scholar 

  88. Harinstein LM, Morgan JW, Russo N. Treatment of dabigatran-associated bleeding: case report and review of the literature. J Pharm Pract. 2013;26(3):264–9.

    PubMed  Google Scholar 

  89. Husari A, Beydoun A, SheikAmmar A, Maakaron JE, Taher A. The untold story of dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. J Thromb Thrombolysis. 2013;35(1):81–2.

    PubMed  Google Scholar 

  90. Kernan L, Ito S, Shirazi F, Boesen K. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol. 2012;50(7):571–3 (Epub 2012/07/18. eng).

    CAS  Google Scholar 

  91. Kim J, Yadava M, An IC, Sayeed A, Laird-Fick HS, Gourineni V, et al. Coagulopathy and extremely elevated PT/INR after dabigatran etexilate use in a patient with end-stage renal disease. Case Rep Med. 2013;2013:131395.

    PubMed Central  PubMed  Google Scholar 

  92. Lal Y, Van Heukelom J. Dabigatran: a cause of hematologic emergency. Am J Med Sci. 2013;346(3):190–3 (Epub 2012/12/12. eng).

    PubMed  Google Scholar 

  93. Legrand M, Mateo J, Aribaud A, Ginistry S, Eftekhari P, Huy P, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171(14):1285–8.

    PubMed  Google Scholar 

  94. Lillo-LeLouet A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost. 2012;108(3):583–5 (Epub 2012/07/12. eng).

    CAS  Google Scholar 

  95. Maddry JK, Amir MK, Sessions D, Heard K. Fatal dabigatran toxicity secondary to acute renal failure. Am J Emerg Med. 2013;31(2):462 e1–2.

  96. Moore CH, Snashall J, Boniface K, Scott J. Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. Am J Emerg Med. 2012;30(9):2082 e1–2.

  97. Nguyen TM, Phelan MP, Werdich XQ, Rychwalski PJ, Huff CM. Subconjunctival hemorrhage in a patient on dabigatran (Pradaxa). Am J Emerg Med. 2013;31(2):455 e3–5.

  98. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood. 2012;119(9):2172–4 (Epub 2012/03/03. eng).

    CAS  PubMed  Google Scholar 

  99. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46(4):e10.

    PubMed  Google Scholar 

  100. FDA. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm2014 (updated 5-13-2014 July 2014).

  101. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72. 12-3059-0492998-00. (Epub 2011/05/18. eng).

  102. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129(9):961–70.

    CAS  PubMed  Google Scholar 

  103. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47–59.

    CAS  PubMed  Google Scholar 

  104. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics or oral dabigatran etexilate. Clin Pharmacokinet. 2010;49(4):259–68.

    CAS  PubMed  Google Scholar 

  105. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61(3):487–9 (Epub 2012/12/12. eng).

    CAS  PubMed  Google Scholar 

  106. Khadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. Thromb Haemost. 2013;109(4):596–605 (Epub 2013/02/08. eng).

    CAS  PubMed  Google Scholar 

  107. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor. Thromb Haemost. 2010;103(6):1116–27 (Epub 2010/03/31. eng).

    PubMed  Google Scholar 

  108. Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother. 2012;46(9):e21 (Epub 2012/08/09. eng).

    PubMed  Google Scholar 

  109. Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol. 2012;52(9):1373–8 (Epub 2011/10/01. eng).

    CAS  PubMed  Google Scholar 

  110. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366(9):864–6.

    CAS  PubMed  Google Scholar 

  111. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272–4 (Epub 2013/03/15. eng).

    CAS  PubMed  Google Scholar 

  112. Stöllberger C, Zuntner G, Bastovansky A, Finsterer J. Cerebral hemorrhage under rivaroxaban. Int J Cardiol. 2013;167:e179–81.

    PubMed  Google Scholar 

  113. Boland M, Murphy M, Murphy M, McDermott E. Acute-onset severe gastrointestinal tract hemorrhage in a postoperative patient taking rivaroxaban after total hip arthroplasty: a case report. J Med Case Rep. 2012;6:129.

    PubMed Central  PubMed  Google Scholar 

  114. Jaeger M, Jeanneret B, Schaeren S. Spontaneous spinal epidural haematoma during Factor Xa inhibitor treatment (rivaroxaban). Eur Spine J. 2012;21(Suppl 4):S433–5.

    PubMed  Google Scholar 

  115. Pavord S, Myers B. Bleeding and thrombotic complications of kidney disease. Blood Rev. 2011;25(6):271–8 (Epub 2011/08/30. eng).

    PubMed  Google Scholar 

  116. Abdelhafiz AH, Wheeldon NM. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice. Am J Geriatr Pharmacother. 2008;6(1):1–11 (Epub 2008/04/09. eng).

    PubMed  Google Scholar 

  117. Piccini JPSS, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KAA, Califf RM. Renal dysfunction as a preductor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) and ATRIA (anticoagulation and risk factors in atrial fibrillation) study cohorts. Circulation. 2013;15(127):224–32.

    Google Scholar 

  118. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70(5):703–12 (Epub 2010/11/03. eng).

    CAS  PubMed Central  PubMed  Google Scholar 

  119. Girgis IG, Patel MR, Peters GR, Moore KT, Mahaffey KW, Nessel CC, Halperin JL, Califf RM, Fox KAA, Becker RC. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol. 2014;54(8):917–27.

    CAS  PubMed  Google Scholar 

  120. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–94 (Epub 2011/08/30. eng).

    CAS  PubMed  Google Scholar 

  121. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–94.

    CAS  PubMed  Google Scholar 

  122. Kubitza D, Becka M, Roth A, Mueck W. Influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor. J Clin Pharmacol. 2013;53(3):249–55.

    PubMed  Google Scholar 

  123. Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KAA. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct, factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;130:138–46.

    CAS  PubMed  Google Scholar 

  124. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KAA, Califf RM. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;11(63):891–900.

    Google Scholar 

  125. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92 (Epub 2011/08/30. eng).

    CAS  PubMed  Google Scholar 

  126. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin—the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63:2141–7.

    PubMed  Google Scholar 

  127. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821–30.

    CAS  PubMed  Google Scholar 

  128. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35(45):3155–79.

    PubMed  Google Scholar 

  129. Rubboli A, Faxon DP, Juhani Airaksinen KE, Schlitt A, Marin F, Bhatt DL, et al. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th anniversary overview. Thromb Haemost. 2014;112(6):1080–7.

    CAS  PubMed  Google Scholar 

  130. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–15.

    CAS  PubMed  Google Scholar 

  131. Janssen Scientific Affairs, LLC. A study exploring two strategies of rivaroxaban (JNJ39039039; BAY-59-7939) and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Janssen Scientific Affairs; 2015 (updated March 2015; cited March 2015). Available from: https://clinicaltrials.gov/ct2/show/NCT01830543.

  132. Boehringer Ingelheim. Evaluation of dual therapy with dabigatran vs triple therapy with warfarin in patients with AF who undergo PCI with stenting (RE-DUAL PCI) (internet). Boehringer Ingelheim; 2015 (updated March 2015; cited March 2015). Available from: https://clinicaltrials.gov/ct2/show/NCT02164864.

  133. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131–6.

    CAS  PubMed  Google Scholar 

  134. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998–2006.

    CAS  PubMed  Google Scholar 

  135. Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014;63(11):1082–7.

    CAS  PubMed  Google Scholar 

  136. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59(13):1168–74.

    CAS  PubMed  Google Scholar 

  137. Winkle RA, Mead RH, Engel G, et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovas Electrophysiol. 2012;23(3):264–8.

    Google Scholar 

  138. Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart rhythm. 2013;10(4):483–9.

    PubMed  Google Scholar 

  139. Imamura K, Yoshida A, Takei A, Fukuzawa K, Kiuchi K, Takami K, et al. Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay. J Interv Card Electrophysiol. 2013;37(3):223–31.

    PubMed Central  PubMed  Google Scholar 

  140. Kaiser DW, Streur MM, Nagarakanti R, Whalen SP, Ellis CR. Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. J Interv Card Electrophysiol. 2013;37(3):241–7.

    PubMed  Google Scholar 

  141. Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F. A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol. 2012;35(1):29–33.

    PubMed  Google Scholar 

  142. Maddox W, Kay GN, Yamada T, Osorio J, Doppalapudi H, Plumb VJ, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Interv Card Electrophysiol. 2013;24(8):861–5.

    Google Scholar 

  143. Haines DE, Mead-Salley M, Salazar M, et al. Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. J Interv Card Electrophysiol. 2013;37:233–9.

    PubMed  Google Scholar 

  144. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2014;63(10):982–8.

    CAS  PubMed  Google Scholar 

  145. Janssen Scientific Affairs. A study exploring two strategies of rivaroxaban (JNJ39039039; BAY-59-7939) and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (internet). Janssen Scientific Affairs; 2015 (updated March 2015; cited March 2015). Available from: https://clinicaltrials.gov/ct2/show/NCT01830543153.

  146. Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy (AXAFA). (Internet). German Atrial Fibrillation Network; 2014 (updated July 2014; cited March 2015). Available from: https://clinicaltrials.gov/ct2/show/NCT02227550.

Download references

Acknowledgments

No potential conflicts of interest and/or sources of funding exist for any of the authors involved in the writing of this manuscript.

Author information

Authors and Affiliations

  1. Fairleigh Dickinson University, 230 Park Avenue, M-SP1-01, Florham Park, NJ, USA

    Julie Kalabalik, Gail B. Rattinger, Jesse Sullivan, Malgorzata Slugocki, Antonia Carbone & Anastasia Rivkin

Authors
  1. Julie Kalabalik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gail B. Rattinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jesse Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Malgorzata Slugocki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Antonia Carbone
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anastasia Rivkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie Kalabalik.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kalabalik, J., Rattinger, G.B., Sullivan, J. et al. Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. Drugs 75, 979–998 (2015). https://doi.org/10.1007/s40265-015-0405-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0405-y

Keywords

Search

Navigation